Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,goodWill,treasuryStock,otherAssets,cash,totalCurrentLiabilities,deferredLongTermAssetCharges,shortLongTermDebt,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,netReceivables,longTermDebt,inventory,accountsPayable,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,otherCashflowsFromInvestingActivities,dividendsPaid,changeToInventory,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,issuanceOfStock,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,esgPopulated,tradeable,currency,market,shortName,exchange,marketState,priceHint,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,exchangeDataDelayedBy,trailingAnnualDividendRate,trailingPE,trailingAnnualDividendYield,epsTrailingTwelveMonths,gmtOffSetMilliseconds,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,fax,industry
t0,IOBCF,133483000,29302700,8657500,,22440000,,21982000,16723000,50553500,25266500,25266500,-156000,-998000,,,,458000,101111000,75844500,50557500,-2826500,,21982000,21982000,4527000,41978000,369165000,141831000,190518000,510996000,42294000,17720000,51883000,27681000,3821000,5676000,27824000,153911000,275712000,7797000,15557000,11583000,47595000,412528000,14701000,156439000,41174000,84458000,41858000,-750000.0,1917000.0,-1894000.0,-3960500.0,-5529000.0,252000.0,28993500.0,-152000.0,36568500.0,2379000.0,500.0,-1127000.0,7130000.0,-1979000.0,-441500.0,4026500.0,-871000.0,,136816000,en-US,US,EQUITY,False,Delayed Quote,19.85,1629901294,0.0,19.33,19.85,19.85,50,4.782,18.54857,1.3014297,0.07016335,19.271015,0.5789852,0.030044354,581658624,4.150983,15,America/New_York,EDT,False,False,USD,us_market,IBA(ION BEAM APPLICATIONS),PNK,PRE,2,0.0,19.85 - 19.85,19.85,0.0,0.0,0,0,finmb_1165466,Other OTC,Ion Beam Applications SA,EUR,93,71,8.64,0.77074045,11.21 - 21.9,-2.0499992,-0.09360727,11.21,21.9,0,0.2,15.483621,0.010075566,1.282,-14400000,0.61,,,21.9,11.21,18.55,19.27,93,71,29.3M,,21.91M,31.13%,27.27%,,,,,,0.24,1.17%,0.20,1.01%,,7.07%,,"Jun 20, 2021",1021:1000,"Jan 12, 2000","Dec 30, 2020","Dec 30, 2020",10.23%,12.93%,5.39%,25.22%,311.96M,10.53,30.90%,136.06M,45.53M,31.92M,1.28,240.10%,153.91M,5.19,86.13M,60.72,1.50,4.78,100.42M,66.98M,Value,1348,Healthcare,1345,7,8,"Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through Proton Therapy and Other Accelerators, and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company has a collaboration agreement with RaySearch Laboratories AB on providing state-of-the-art integrated solutions. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.",Louvain-la-Neuve,32 1 047 58 11,9,1609372800,1622505600,7,Belgium,http://www.iba-worldwide.com,86400,8,"3, Chemin du Cyclotron",32 1 047 58 10,Medical Devices
t-1,IOBCF,133483000,29302700,8657500,,22440000,,21982000,16723000,50553500,25266500,25266500,-156000,-998000,,,,458000,101111000,75844500,50557500,-2826500,,21982000,21982000,4527000,41978000,369165000,141831000,190518000,510996000,42294000,17720000,51883000,27681000,3821000,5676000,27824000,153911000,275712000,7797000,15557000,11583000,47595000,412528000,14701000,156439000,41174000,84458000,41858000,-750000.0,1917000.0,-1894000.0,-3960500.0,-5529000.0,252000.0,28993500.0,-152000.0,36568500.0,2379000.0,500.0,-1127000.0,7130000.0,-1979000.0,-441500.0,4026500.0,-871000.0,,136816000,en-US,US,EQUITY,False,Delayed Quote,19.85,1629901294,0.0,19.33,19.85,19.85,50,4.782,18.54857,1.3014297,0.07016335,19.271015,0.5789852,0.030044354,581658624,4.150983,15,America/New_York,EDT,False,False,USD,us_market,IBA(ION BEAM APPLICATIONS),PNK,PRE,2,0.0,19.85 - 19.85,19.85,0.0,0.0,0,0,finmb_1165466,Other OTC,Ion Beam Applications SA,EUR,93,71,8.64,0.77074045,11.21 - 21.9,-2.0499992,-0.09360727,11.21,21.9,0,0.2,15.483621,0.010075566,1.282,-14400000,0.61,,,21.9,11.21,18.55,19.27,93,71,29.3M,,21.91M,31.13%,27.27%,,,,,,0.24,1.17%,0.20,1.01%,,7.07%,,"Jun 20, 2021",1021:1000,"Jan 12, 2000","Dec 30, 2020","Dec 30, 2020",10.23%,12.93%,5.39%,25.22%,311.96M,10.53,30.90%,136.06M,45.53M,31.92M,1.28,240.10%,153.91M,5.19,86.13M,60.72,1.50,4.78,100.42M,66.98M,Value,1348,Healthcare,1345,7,8,"Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through Proton Therapy and Other Accelerators, and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company has a collaboration agreement with RaySearch Laboratories AB on providing state-of-the-art integrated solutions. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.",Louvain-la-Neuve,32 1 047 58 11,9,1609372800,1622505600,7,Belgium,http://www.iba-worldwide.com,86400,8,"3, Chemin du Cyclotron",32 1 047 58 10,Medical Devices
t-2,IOBCF,88135000,29302700,7903500,,-5913000,,-6021500,14540500,17474000,-5098500,-5098500,128500,-1400500,,,,108500,54866500,59965000,37392500,-814500,,-6021500,-6021500,6202000,41978000,342746000,98158000,185736000,440904000,42294000,3555000,7876000,10067000,3821000,6010000,28360000,95924000,260286000,7517000,12988000,11917000,47892000,337688000,16941000,122856000,47367000,115353000,33945000,-50000.0,-834500.0,-906500.0,11720500.0,12213000.0,-264000.0,24917000.0,-33500.0,13644000.0,2739500.0,-500.0,-1127000.0,5898000.0,12376000.0,-551500.0,-249500.0,-406500.0,1044000.0,77402000,en-US,US,EQUITY,False,Delayed Quote,19.85,1629901294,0.0,19.33,19.85,19.85,50,4.782,18.54857,1.3014297,0.07016335,19.271015,0.5789852,0.030044354,581658624,4.150983,15,America/New_York,EDT,False,False,USD,us_market,IBA(ION BEAM APPLICATIONS),PNK,PRE,2,0.0,19.85 - 19.85,19.85,0.0,0.0,0,0,finmb_1165466,Other OTC,Ion Beam Applications SA,EUR,93,71,8.64,0.77074045,11.21 - 21.9,-2.0499992,-0.09360727,11.21,21.9,0,0.2,15.483621,0.010075566,1.282,-14400000,0.61,,,21.9,11.21,18.55,19.27,93,71,29.3M,,21.91M,31.13%,27.27%,,,,,,0.24,1.17%,0.20,1.01%,,7.07%,,"Jun 20, 2021",1021:1000,"Jan 12, 2000","Dec 30, 2020","Dec 30, 2020",10.23%,12.93%,5.39%,25.22%,311.96M,10.53,30.90%,136.06M,45.53M,31.92M,1.28,240.10%,153.91M,5.19,86.13M,60.72,1.50,4.78,100.42M,66.98M,Value,1348,Healthcare,1345,7,8,"Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through Proton Therapy and Other Accelerators, and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company has a collaboration agreement with RaySearch Laboratories AB on providing state-of-the-art integrated solutions. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.",Louvain-la-Neuve,32 1 047 58 11,9,1609372800,1622505600,7,Belgium,http://www.iba-worldwide.com,86400,8,"3, Chemin du Cyclotron",32 1 047 58 10,Medical Devices
t-3,IOBCF,88135000,29302700,7903500,,-5913000,,-6021500,14540500,17474000,-5098500,-5098500,128500,-1400500,,,,108500,54866500,59965000,37392500,-814500,,-6021500,-6021500,6202000,41978000,342746000,98158000,185736000,440904000,42294000,3555000,7876000,10067000,3821000,6010000,28360000,95924000,260286000,7517000,12988000,11917000,47892000,337688000,16941000,122856000,47367000,115353000,33945000,-50000.0,-834500.0,-906500.0,11720500.0,12213000.0,-264000.0,24917000.0,-33500.0,13644000.0,2739500.0,-500.0,-1127000.0,5898000.0,12376000.0,-551500.0,-249500.0,-406500.0,1044000.0,77402000,en-US,US,EQUITY,False,Delayed Quote,19.85,1629901294,0.0,19.33,19.85,19.85,50,4.782,18.54857,1.3014297,0.07016335,19.271015,0.5789852,0.030044354,581658624,4.150983,15,America/New_York,EDT,False,False,USD,us_market,IBA(ION BEAM APPLICATIONS),PNK,PRE,2,0.0,19.85 - 19.85,19.85,0.0,0.0,0,0,finmb_1165466,Other OTC,Ion Beam Applications SA,EUR,93,71,8.64,0.77074045,11.21 - 21.9,-2.0499992,-0.09360727,11.21,21.9,0,0.2,15.483621,0.010075566,1.282,-14400000,0.61,,,21.9,11.21,18.55,19.27,93,71,29.3M,,21.91M,31.13%,27.27%,,,,,,0.24,1.17%,0.20,1.01%,,7.07%,,"Jun 20, 2021",1021:1000,"Jan 12, 2000","Dec 30, 2020","Dec 30, 2020",10.23%,12.93%,5.39%,25.22%,311.96M,10.53,30.90%,136.06M,45.53M,31.92M,1.28,240.10%,153.91M,5.19,86.13M,60.72,1.50,4.78,100.42M,66.98M,Value,1348,Healthcare,1345,7,8,"Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through Proton Therapy and Other Accelerators, and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company has a collaboration agreement with RaySearch Laboratories AB on providing state-of-the-art integrated solutions. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.",Louvain-la-Neuve,32 1 047 58 11,9,1609372800,1622505600,7,Belgium,http://www.iba-worldwide.com,86400,8,"3, Chemin du Cyclotron",32 1 047 58 10,Medical Devices
